Moreover, FOXD2-AS1 over-expression has been shown to lead to antitumor drug resistance in various cancers, including esophageal squamous-cell carcinoma [26] and hepatocellular carcinoma [27]. This evidence concerns the gene FOXD2 and hepatocellular carcinoma.